Celltrion is expanding its presence in Italy’s pharmaceutical sector with strong sales of autoimmune and anticancer drugs. The Korean biopharmaceutical company recently won multiple bids to supply these treatments across several Italian states. This move strengthens its foothold in one of Europe’s most important healthcare markets.
The company secured contracts for its autoimmune medicine, Steqeyma, in Veneto, Trentino-Alto Adige, and Sardinia. It plans to supply the drug to these regions throughout the first half of the year. Steqeyma quickly gained market traction after its Italian launch, showing high demand from healthcare providers.
Celltrion’s flagship autoimmune drug Remsima continues to perform well in Italy. The company won a new supply bid for the state of Umbria. Additionally, Remsima SC renewed its contract with Puglia, keeping its presence in all 20 Italian states. Market research from IQVIA estimates that Remsima and Remsima SC held a combined 66 percent share of Italy’s autoimmune drug market in the first quarter.
The company also expanded its anticancer portfolio in Italy. Truxima secured a bid in Lazio, while Vegzelma won in Umbria. These two products account for 29 percent and 30 percent of their respective market segments. With more bids scheduled later this year, Celltrion expects further growth in its anticancer drug sales.
According to the company, these results reflect strong trust from Italian healthcare stakeholders. Italy’s medical industry is a major player in Europe, making it a strategic target for Celltrion’s expansion. The company’s broad product lineup, covering both autoimmune and anticancer drugs, strengthens its competitive position.
Celltrion aims to build on this momentum by launching additional products and securing new contracts. It plans to focus on increasing prescriptions and market share through direct engagement with healthcare providers. The strategy includes targeting both hospital networks and regional healthcare authorities to sustain growth.
The success of Celltrion’s autoimmune and anticancer drugs in Italy also demonstrates the company’s global competitiveness. By expanding in a highly regulated and competitive market, the firm reinforces its brand reputation. Furthermore, these achievements support its long-term goal of becoming a leading global biopharmaceutical company.
